Member Info for Energyshares

Bloody LSE ?? 0-5 ???
Can’t even put Chinese writing now.

The Education minister has just been on SKY News and said he is delighted every person in the UK can now read at least one sentence in Mandarin.

I read it straight away.

?? 0-5 ???

A highways agency warning said anyone travelling in icy conditions should take a shovel, blankets, sleeping bag, extra clothing, including a scarf, hat, gloves, 24 hour supply of food and drink, de-icer, rock salt, torch, safety triangle, tow rope, petrol can, first aid kit and jump leads................

I looked a right idiot on the bus this morning. :)

Keep going Poirot, I enjoy your posts :)

“minimally invasive and can cause no harm unless you decide to eat the test.”

Brilliant MrR

https://www.saturnpass.com/how-it-works/

Saturnpass, The Medusa19 App they have created for their tests.

I like this paragraph:
Test At Home
Our app provides test validation with tamper-proof technology for accurate result reporting. Users can test at home using the free NHS home test kits and verify their results via the app.
We also have relationships with major manufacturers of LFD COVID tests across the globe, to supply additional tests.

They have everything set up just waiting for that HUA green light ……Then Boooom.

Up and running thanks mate :)

Interesting it was 3.76% at our peak in March.

So are we all worrying to much about the short…

Could this be what EU asked for what Jay talking about yesterday, version 3 of Affidx Safety Data sheet submitted dated 08/09/2021.
Version 2 was submitted 3/09/2021

https://mologic.co.uk/wp-content/uploads/2021/09/SDS-AffiDX-SARS-CoV-2-Lateral-Flow-Test_EN.pdf

Not just Bioserve selling Avacta products look at this Spanish site

https://mobile.labmedica.es/expo/company/22894/products


SARS-CoV-2 Antigen Lateral Flow Test  
Modelo: AffiDX SARS-CoV-2 Antigen Lateral Flow Test

The Avacta AffiDX SARS-CoV-2 Antigen Lateral Flow Test is a qualitative in vitro diagnostic (IVD) test to detect SARS-CoV-2 antigen in human anterior nasal swabs. It is an ideal solution for point-of-care and decentralized testing to identify individuals with higher viral loads of SARS-CoV-2 that increase the likelihood of transmitting the infection to others. The test is wholly developed and manufactured in the UK utilizing accurate, flexible Affimer technology, and validated against emerging variants of SARS-CoV-2.

Please send a price quote for the name:
undefined: SARS-CoV-2 Antigen Lateral Flow Test
Model: AffiDX SARS-CoV-2 Antigen Lateral Flow Test

Reagents  
Modelo: Affimer Reagents in Affinity Purification

Affimer technology offers unique solutions in the field of affinity purification through the ability to develop highly specific and stable capture reagents for a wide-range of novel targets. The robust nature of Affimer reagents allows them to withstand industrial cleaning-in-place conditions without significant leaching, while highly reproducible manufacturing assures the consistency of supply. Affimer reagents can be engineered to orient the binder on the resin to optimize target binding. Implementing Affimer reagents in affinity chromatography and bioprocessing applications opens up the potential of unmet needs in this field.

Immunoassay Reagents  
Modelo: Affimer Immunoassay Reagents

Affimer reagents have been successfully used to detect and quantify antigens across a broad range of immunoassay platforms. Highly specific Affimer binders can be generated to a wide variety of novel targets and routinely show minimal matrix effects within the assay environment. The application of these binders as capture reagents within an immunoassay can increase the potential specificity and dynamic range of the assay, delivering improved accuracy and the opportunity to multiplex sample analysis.

It is his cv on the website FFS

FDA Approval

We will have FDA approval within 45-60 days.

That’s makes it sometime between Christmas Eve & 8th Jan 2022 if Steve is right.

Steve Crummey has more than 30 years of entrepreneurial experience in starting, growing, developing, and turning around multimillion-dollar companies in highly competitive markets.
With a strong track record of fiscal growth, innovative strategies and operations leadership, his range of expertise includes maximizing human and financial resources, fostering network of successful partnerships, and devising and applying creative growth strategies to suit any industry – global or domestic.
Steve is a proactive leader noted for strategic depth, skillful market planning, and effective problem-solving skills. His leadership abilities are enhanced by integrity, efficiency, and wealth of experience in expanding market share.
During his career, Steve led worldwide sales for Lotus Development & Avid Technologies, increasing revenue 20x and 14x, respectively. He also founded one of the first companies to successfully use SaaS as its business model, Intranets; served as its CEO and negotiated significant OEM agreement with Compaq Computer.

I posted this a few days ago
a website based in Boston USA selling Medusa saliva test.

Covid Rapid Exam

Once HUA arrives Medusa are going to manufacture sell Affidx in enormous numbers.

Just look at this website,they are setting up lots of partnerships this one mentions their saliva test but once Affidx arrives Boooom.

Their management team has a lot of experience too.

We are currently engaged worldwide, including in Argentina, Brazil, Dominican Republic, Egypt, Germany, India, Paraguay, Saudi Arabia, Sweden, UAE, United States, and Uruguay.

https://www.covidrapidexam.com/

So I just filled in contact form 15 minutes ago and received this reply straight away.

I think we are going to have a great Christmas……

If you don’t believe fill in the form and ask yourself….

Message:
Hi ?Are you supplying Medusa antigen test by Avacta (Affidx)?If so when and is it being sold in USA
?Regards?Bill

Re: Form Submission - Covid Rapid Exam Form

stevecrummey**********

Thanks Bill. We will have FDA approval within 45-60 days.

Looks like AS has been right to focus on Europe.

Daily Covid infections hit an all-time high in Germany Thursday as the World Health Organization warned that another 500,000 people could die across Europe.

https://amp.france24.com/en/europe/20211104-covid-cases-hit-new-record-in-germany-as-who-warns-of-spread-in-europe

Once HUA arrives Medusa are going to manufacture sell Affidx in enormous numbers.

Just look at this website,they are setting up lots of partnerships this one mentions their saliva test but once Affidx arrives Boooom.

Their management team has a lot of experience too.

We are currently engaged worldwide, including in Argentina, Brazil, Dominican Republic, Egypt, Germany, India, Paraguay, Saudi Arabia, Sweden, UAE, United States, and Uruguay.

https://www.covidrapidexam.com/

Point very confident in radioligands drugs building a manufacturing facility in Indianapolis.
Pages 4 & 5 link below.

We are also advancing two early-stage programs, PNT2001 and PNT2004, as well as a tumor microenvironment targeting technology platform that could be applied across a variety of radioligands.
 
TABLE OF CONTENTS
 
PNT2001, our next-generation PSMA-targeting product candidate, will be evaluated in preclinical studies to assess its potential for the treatment of non-metastatic castration sensitive prostate cancer, or nmCSPC. PNT-2004, a fibroblast activation protein-a, or FAP-a, targeted radioligand, will be evaluated for the treatment of solid tumors by targeting a key characteristic of almost all cancers, the presence of FAP-a in the tumor microenvironment. Our tumor microenvironment targeting technology is a prodrug platform which enables radioligands to be activated by FAP-a in the tumor microenvironment, potentially expanding the therapeutic window of radiopharmaceutical product candidates. PNT2001, PNT2004 and the programs contemplated under the tumor microenvironment targeting prodrug platform are in preclinical development and will be evaluated for potential use with both lutetium-177 and actinium-225.
We are leveraging our expertise in radiopharmaceutical manufacturing to develop processes that enable us to efficiently manufacture our radiopharmaceutical product candidates at scale. Manufacturing and supply chain are key success factors in the radiopharmaceutical industry. Both the raw ingredients and finished radiopharmaceutical products cannot be stored for long periods of time due to decay of the radioactive isotope. As a result, radiopharmaceuticals are manufactured on-demand, with a just-in-time supply chain. To lead in this category, we are building our own manufacturing facility in Indianapolis, Indiana that will incorporate both radioisotope and radioligand production. We plan to provide clinical supply from our facility in the fourth quarter of 2021 and expect that this facility will provide adequate production capacity to meet future commercial demands for our product candidates, if approved.

https://www.sec.gov/Archives/edgar/data/1811764/000110465921098307/tm2123357-1_s1.htm

BITL
Thanks for your feedback I was just starting a debate.
Green boxes but don’t care much easier read on here now.

There has been arguments on here over the last 18 months that Avacta has to RNS as soon as they have market sensitive information.
Well this blows that theory away.

From today’s RNS

notes that, as of 1 November 2021, the UK Health Security Agency's Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 ("CTDA regulations") have come into force. Consistent with these new regulations the Company has suspended, as of 1 November 2021, further sales of its AffiDX SARS-CoV-2 Lateral Flow Rapid Antigen Test in the UK until the ongoing desktop evaluation of the test has been successfully completed by the Agency and the test subsequently is put on the CTDA register for approved products. This is a new requirement for the supply of any COVID-19 test in the UK and is over and above the CE mark and successful registration of Company's AffiDX test with the MHRA which was announced on 7 June 2021.

So Affidx suspended yesterday markets open,but doesn’t RNS until 2nd Nov.

Anyone have any thoughts why RNS not put out yesterday ?

It wouldn’t let me top up, just managed to add funds now .

Looking at the buys MM ‘s must of took out some stop losses in the 90’s to pick up shares.
Can’t see anyone selling that low